

**We Claim:**

1. A method for the prevention of the loss of visual acuity associated with AMD, which comprises, juxtasclerally administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol.

2. The method of Claim 1 wherein the compound is administered as a juxtascleral depot.

3. The method of Claim 2 wherein the depot comprises 3 mg – 30 mg of compound.

4. The method of Claim 3 wherein the depot comprises 15 mg of compound.

5. A method for maintaining visual acuity in a person suffering from AMD, which comprises, juxtasclerally administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol.

6. The method of Claim 5 wherein the compound is administered as a juxtascleral depot.

7. The method of Claim 6 wherein the depot comprises 3 mg – 30 mg of compound.

8. The method of Claim 7 wherein the depot comprises 15 mg of compound.

9. A method for the inhibition of lesion growth associated with AMD, which comprises, juxtasclerally administering a pharmaceutically effective amount of the compound anecortave acetate or its corresponding alcohol.

10. The method of Claim 9 wherein the compound is administered as a juxtascleral depot.

11. The method of Claim 10 wherein the depot comprises 3 mg – 30 mg of compound.

12. The method of Claim 11 wherein the depot contains 15 mg of compound.

13. The method of Claim 1, 5, or 9 wherein the compound is administered in a juxtascleral implant.

5 14. The use of anecortave acetate or its corresponding alcohol for the preparation of a medicament for the prevention of the loss of visual acuity associated with AMD.

10 15. The use of anecortave acetate or its corresponding alcohol for the preparation of a medicament for maintaining visual acuity in a person suffering from AMD.

16. The use of anecortave acetate or its corresponding alcohol for the preparation of a medicament for the inhibition of lesion growth associated with AMD.

15 17. The use according to Claims 14-16 wherein the preparation is administered as a juxtascleral depot.

18. The use according to Claim 17 wherein the depot comprises 3 mg – 30 mg of anecortave acetate or its corresponding alcohol.

20 19. The use according to Claim 18 wherein the depot comprises 15 mg of anecortave acetate or its corresponding alcohol.

25 20. The use according to Claims 14 – 16 wherein the preparation is administered as a juxtascleral implant.